Business Context and Reporting Period
Company: LiveRamp Holdings, Inc. (NYSE: RAMP)
Filing Type: Form 8-K (Current Report)
Date of Report: May 15, 2026 (Earliest event reported)
Principal Event: Entry into a Material Definitive Agreement for a merger with MMS USA Holdings, Inc., a wholly-owned subsidiary of Publicis Groupe S.A.
Key Financial Metrics and Transaction Terms
Merger Consideration: $38.50 in cash per share of LiveRamp common stock.
Equity Award Treatment: Outstanding options, restricted stock awards (RSAs), restricted stock units (RSUs), and performance stock units (PSUs) will convert to restricted cash awards based on the merger consideration and specific vesting/performance calculations.
Termination Fees: $32,350,000 payable by either party under specific termination scenarios (e.g., superior proposal by LiveRamp or regulatory failure by Parent).
Executive Retention Awards: Cash awards totaling $2.5 million granted to four executives (Scott Howe, Lauren Dillard, Jerry Jones, Vihan Sharma), payable 30 days post-closing subject to continued employment.
Financial Results: The filing references a press release (Exhibit 99.1) regarding Q4 and fiscal year 2026 results ended March 31, 2026, but does not contain specific revenue, profit, or cash flow figures within this text.
Material Changes and Conditions
- Corporate Structure: Upon closing, LiveRamp will become a direct wholly-owned subsidiary of MMS USA Holdings, Inc. (Parent) and a subsidiary of Publicis Groupe S.A.
- Delisting: LiveRamp common stock will be delisted from the New York Stock Exchange and deregistered under the Exchange Act upon consummation.
- Bylaw Amendment: The Board approved the Third Amended and Restated Bylaws, designating the Court of Chancery of Delaware as the exclusive forum for internal corporate claims and federal district courts for Securities Act claims.
- Conditions to Closing: Includes stockholder approval, absence of laws prohibiting the merger, expiration of HSR waiting periods, receipt of foreign investment approvals (including CFIUS), and no material adverse effect.
Guidance, Outlook, and Risks
Outlook: The Board unanimously determined the transaction is fair and in the best interests of stockholders. The conference call for Q4 2026 results was canceled due to the merger announcement.
Risks and Contingencies:
- Regulatory Approval: Closing is contingent on CFIUS and other antitrust approvals; failure to obtain these by the "Outside Date" (May 16, 2027, extendable by 3 months) may trigger termination.
- Superior Proposal: LiveRamp retains a "fiduciary out" to negotiate a superior proposal if it determines the current agreement is no longer in the best interest of stockholders.
- Integration Risks: Potential failure to realize synergies, integration costs, retention of key personnel, and client retention.
- Forward-Looking Statements: Actual results may differ materially due to risks outside the parties' control.
Investor Verification Checklist
- Verify the final proxy statement for detailed financial data regarding Q4 and fiscal year 2026, as specific numbers are not in this 8-K.
- Confirm the status of regulatory approvals, specifically CFIUS and antitrust clearances, which are critical closing conditions.
- Review the specific vesting acceleration terms for equity awards, particularly for PSUs granted after December 31, 2025.
- Monitor for any "Superior Proposal" announcements that could alter the transaction terms or lead to termination.
- Check the definitive proxy statement for the exact timing of the shareholder vote and the proposed closing date.